In addition to genetic predisposition, carcinoembryonic antigen (CEA), C-reactive protein, serum CD26, and other biomarkers have recently been demonstrated to have the potential to complement CRC screening methods [5–7]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.